RGBP (Regen BioPharma) E10: $0.00 (As of Mar. 2026)


What is Regen BioPharma E10?

Regen BioPharma RGBP +33.33% E10 is $0.00 as of Mar. 2026. The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Regen BioPharma's adjusted earnings per share data for the three months ended in Mar. 2026 was $0.000. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $0.00 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-26), Regen BioPharma's current stock price is $0.0002. Regen BioPharma's E10 for the quarter that ended in Mar. 2026 was $0.00. Regen BioPharma's Shiller PE Ratio of today is .


Regen BioPharma  (OTCPK:RGBP) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Regen BioPharma E10 Related Terms


Regen BioPharma E10 Historical Data

* Premium members only.

The historical data trend for Regen BioPharma's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regen BioPharma E10 Chart

Regen BioPharma Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -17.81 -16.80 -15.19

Regen BioPharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -15.49 -15.19 -14.53 0.00

RGBP vs ENDV, ADTX, SCPX: E10 Comparison

For the Biotechnology subindustry, Regen BioPharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regen BioPharma Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regen BioPharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Regen BioPharma's Shiller PE Ratio falls into.



Regen BioPharma E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Regen BioPharma's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/330.2130*330.2130
=0.000

Current CPI (Mar. 2026) = 330.2130.

Regen BioPharma Quarterly Data

per share eps CPI Adj_EPS
201606 -5.850 241.018 -8.015
201609 -5.400 241.428 -7.386
201612 -2.925 241.432 -4.001
201703 -6.975 243.801 -9.447
201706 -14.250 244.955 -19.210
201709 -7.275 246.819 -9.733
201712 -14.625 246.524 -19.590
201803 -5.850 249.554 -7.741
201806 -0.525 251.989 -0.688
201809 -4.350 252.439 -5.690
201812 0.525 251.233 0.690
201903 -0.825 254.202 -1.072
201906 -38.550 256.143 -49.698
201909 2.347 256.759 3.018
201912 2.250 256.974 2.891
202003 -1.950 258.115 -2.495
202006 1.200 257.797 1.537
202009 0.525 260.280 0.666
202012 0.587 260.474 0.744
202103 0.150 264.877 0.187
202106 -1.575 271.696 -1.914
202109 -0.188 274.310 -0.226
202112 0.750 278.802 0.888
202203 -11.020 287.504 -12.657
202206 9.555 296.311 10.648
202209 -0.005 296.808 -0.006
202212 0.225 296.797 0.250
202303 -0.015 301.836 -0.016
202306 -0.015 305.109 -0.016
202309 -0.050 307.789 -0.054
202312 -0.020 306.746 -0.022
202403 -0.015 312.332 -0.016
202406 -0.015 314.175 -0.016
202409 -0.030 315.301 -0.031
202412 -0.065 315.605 -0.068
202503 0.000 319.799 0.000
202506 -0.010 322.561 -0.010
202509 -0.020 324.800 -0.020
202512 -0.010 324.054 -0.010
202603 0.000 330.213 0.000

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $0.00 mean?
Regen BioPharma (RGBP) has a E10 of $0.00 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Regen BioPharma and its competitors.
Is Regen BioPharma's E10 too high?
Regen BioPharma's current E10 is $0.00.
How does Regen BioPharma's E10 compare to ENDV and ADTX?
Regen BioPharma's E10 of $0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Regen BioPharma and its competitors. Regen BioPharma's current E10 is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regen BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Regen BioPharma (RGBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.00 — trading 99% below its estimated fair value. The current E10 is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Regen BioPharma (RGBP), the current E10 is $0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regen BioPharma Business Description

Other Exchanges RGBPP.PFD:USA
Address 8697 La Mesa Boulevard, Suite C, La Mesa, CA, USA, 91942
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.